Trials / Terminated
TerminatedNCT05099822
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-center, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of CC-97489 in Healthy Adult Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study aims to evaluate the safety, tolerability, of CC-97489
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-97489 | Specified dose on specified days |
| OTHER | Placebo | Specified dose on specified days |
Timeline
- Start date
- 2020-03-13
- Primary completion
- 2022-07-11
- Completion
- 2022-07-11
- First posted
- 2021-10-29
- Last updated
- 2023-12-14
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT05099822. Inclusion in this directory is not an endorsement.